1. DOP83 Normalisation of biomarkers and improvement in clinical outcomes in patients with Crohn's Disease treated with risankizumab in the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. (21st January 2022) Authors: Atreya, R; Feagan, B; Shchukina, O; Jairath, V; Rieder, F; Hisamatsu, T; Siegmund, B; Rizzo, J; Kligys, K; Neimark, E; Song, A; Zambrano, J; Mallick, M; Cheng, E; Armuzzi, A Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i126 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. LBA44Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067). (23rd October 2018) Authors: Hodi, F S; Chiarion-Sileni, V; Gonzalez, R; Grob, J J; Rutkowski, P; Cowey, C L; Lao, C; Schadendorf, D; Wagstaff, J; Dummer, R; Ferrucci, P F; Smylie, M; Hill, A G; Hogg, D; Marquez-Rodas, I; Jiang, J; Rizzo, J; Larkin, J; Wolchok, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P16 ATRIAL FIBRILLATION INCIDENCE IN SARS–COV–2 INFECTED PATIENTS: PREDICTORS AND RELATIONSHIP WITH IN–HOSPITAL MORTALITY. (18th May 2022) Authors: Maloberti, A; Giannattasio, C; Rebora, P; Occhino, G; Ughi, N; Rizzo, J; Fabbri, S; Leidi, F; Cartella, I; Algeri, M; Scarpellini, S; Rossetti, C; Epis, O; Molon, G; Bonfanti, P; Valsecchi, M; Genovesi, S Journal: European heart journal supplements Issue: Volume 24(2022)Supplement C Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗